These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10607671)

  • 21. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity.
    Kriwacki RW; Hengst L; Tennant L; Reed SI; Wright PE
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11504-9. PubMed ID: 8876165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin-cyclin-dependent kinase regulatory response is linked to substrate recognition.
    Cuomo ME; Platt GM; Pearl LH; Mittnacht S
    J Biol Chem; 2011 Mar; 286(11):9713-25. PubMed ID: 21233209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impairment of rat postnatal lung alveolar development by glucocorticoids: involvement of the p21CIP1 and p27KIP1 cyclin-dependent kinase inhibitors.
    Corroyer S; Schittny JC; Djonov V; Burri PH; Clement A
    Pediatr Res; 2002 Feb; 51(2):169-76. PubMed ID: 11809910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes.
    Flink IL; Oana S; Maitra N; Bahl JJ; Morkin E
    J Mol Cell Cardiol; 1998 Mar; 30(3):563-78. PubMed ID: 9515032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
    Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
    Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
    Chen WJ; Chang CY; Lin JK
    Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of a viral cyclin, a positive regulator of cyclin-dependent kinase 6.
    Schulze-Gahmen U; Jung JU; Kim SH
    Structure; 1999 Mar; 7(3):245-54. PubMed ID: 10368294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substrate specificity of cyclins determined by electrostatics.
    Lee HJ; Chua GH; Krishnan A; Lane DP; Verma CS
    Cell Cycle; 2007 Sep; 6(18):2219-26. PubMed ID: 17890901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cdk pathway: cyclin-dependent kinases and cyclin-dependent kinase inhibitors.
    Gitig DM; Koff A
    Mol Biotechnol; 2001 Oct; 19(2):179-88. PubMed ID: 11725487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex.
    Ellis M; Chew YP; Fallis L; Freddersdorf S; Boshoff C; Weiss RA; Lu X; Mittnacht S
    EMBO J; 1999 Feb; 18(3):644-53. PubMed ID: 9927424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maize CDKA2;1a and CDKB1;1 kinases have different requirements for their activation and participate in substrate recognition.
    López-Hernández MN; Vázquez-Ramos JM
    FEBS J; 2023 May; 290(9):2463-2488. PubMed ID: 36259272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selectivity and potency of cyclin-dependent kinase inhibitors.
    Sridhar J; Akula N; Pattabiraman N
    AAPS J; 2006 Mar; 8(1):E204-21. PubMed ID: 16584130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2.
    Kitagawa M; Higashi H; Jung HK; Suzuki-Takahashi I; Ikeda M; Tamai K; Kato J; Segawa K; Yoshida E; Nishimura S; Taya Y
    EMBO J; 1996 Dec; 15(24):7060-9. PubMed ID: 9003781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
    Brown NR; Noble ME; Endicott JA; Johnson LN
    Nat Cell Biol; 1999 Nov; 1(7):438-43. PubMed ID: 10559988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of substrate specificity and cyclin Y binding of PCTAIRE-1 kinase.
    Shehata SN; Hunter RW; Ohta E; Peggie MW; Lou HJ; Sicheri F; Zeqiraj E; Turk BE; Sakamoto K
    Cell Signal; 2012 Nov; 24(11):2085-94. PubMed ID: 22796189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formation of p27-CDK complexes during the human mitotic cell cycle.
    Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
    Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cell cycle inhibitor p21CIP is phosphorylated by cyclin A-CDK2 complexes.
    Jaumot M; Estañol JM; Casanovas O; Graña X; Agell N; Bachs O
    Biochem Biophys Res Commun; 1997 Dec; 241(2):434-8. PubMed ID: 9425288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bound to activate: conformational consequences of cyclin binding to CDK2.
    Radzio-Andzelm E; Lew J; Taylor S
    Structure; 1995 Nov; 3(11):1135-41. PubMed ID: 8591024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.